DETROIT, Mich. — Cycle Pharmaceuticals has announced the U.S. launch of PHYRAGO (dasatinib) tablets, marking the company’s entry into oncology. The new treatment is being introduced in partnership with Handa Therapeutics, LLC, and will be available exclusively through the specialty pharmacy Onco360. Distribution will be managed by McKesson, Cencora, and Cardinal Health.
PHYRAGO is a tyrosine kinase inhibitor approved for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL), as well as pediatric patients aged one year and older with Ph+ CML in chronic phase and newly diagnosed Ph+ ALL.
The product is bioequivalent to Sprycel (dasatinib) tablets and offers an important clinical advantage: it allows patients to take proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) concurrently, helping manage gastric acid disorders. To support patient access, Cycle Pharmaceuticals will provide assistance through its Cycle Vita program, which offers medication access, financial support, and personalized clinical guidance.
“We are honored to introduce PHYRAGO as a new treatment option for people living with Ph+ leukemia,” said Steve Fuller, Chief Strategy Officer at Cycle Pharmaceuticals. “We understand the daily challenges that come with managing Ph+ CML and Ph+ ALL, and our goal is to ease that burden—not just with an improved formulation of dasatinib, but through the individualized care and hands-on support offered by our Cycle Vita program. By enabling more flexibility in co-medication and providing a dedicated support team, we’re committed to helping patients and their families navigate treatment with greater confidence and peace of mind.”
Since 2017, Cycle Pharmaceuticals has developed and commercialized therapies designed to simplify treatment for patients with rare and serious diseases. Its growing portfolio includes NITYR (nitisinone), SAJAZIR (icatibant), JAVYGTOR (sapropterin dihydrochloride), TASCENSO ODT (fingolimod), ORMALVI (dichlorphenamide), VENXXIVA (tiopronin), BAFIERTAM (monomethyl fumarate), and HARLIKU (nitisinone).
PHYRAGO joins this expanding lineup as Cycle’s first oncology therapy in the U.S., furthering its mission to combine innovative science with patient-centered support.
